# Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection

> **NCT00782353** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 35 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** ANA598 200 mg bid or placebo
- **DRUG:** ANA598 400 mg bid or placebo
- **DRUG:** ANA598 800 mg bid or placebo

## Key facts

- **NCT ID:** NCT00782353
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2012-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00782353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00782353, "Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00782353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*